Mineralys Therapeutics, Inc. MLYS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s accrued expenses?
- Mineralys Therapeutics, Inc. (MLYS) reported accrued expenses of $13.6M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Mineralys Therapeutics, Inc.'s accrued expenses increased by 4.5% year-over-year, from $13.01M to $13.6M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s accrued expenses?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s accrued expenses has grown at a 28.6% compound annual growth rate (CAGR), from $6.16M to $13.1M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.